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Abstract
Background: Hepatitis C virus (HCV) infection is a global health problem. A number of studies have implicated
a direct role of cellular lipid metabolism in the HCV life cycle and inhibitors of the mevalonate pathway have been
demonstrated to result in an antiviral state within the host cell. Transcriptome profiling was conducted on Huh-
7 human hepatoma cells bearing subgenomic HCV replicons with and without treatment with 25-
hydroxycholesterol (25-HC), an inhibitor of the mevalonate pathway that alters lipid metabolism, to assess
metabolic determinants of pro- and antiviral states within the host cell. These data were compared with gene
expression profiles from HCV-infected chimpanzees.
Results: Transcriptome profiling of Huh-7 cells treated with 25-HC gave 47 downregulated genes, 16 of which
are clearly related to the mevalonate pathway. Fewer genes were observed to be upregulated (22) in the presence
of 25-HC and 5 genes were uniquely upregulated in the HCV replicon bearing cells. Comparison of these gene
expression profiles with data collected during the initial rise in viremia in 4 previously characterized HCV-infected
chimpanzees yielded 54 overlapping genes, 4 of which showed interesting differential regulation at the mRNA level
in both systems. These genes are PROX1, INSIG-1, NK4, and UBD. The expression of these genes was perturbed
with siRNAs and with overexpression vectors in HCV replicon cells, and the effect on HCV replication and
translation was assessed. Both PROX1 and NK4 regulated HCV replication in conjunction with an antiviral state
induced by 25-hydroxycholesterol.
Conclusion: Treatment of Huh-7 cells bearing HCV replicons with 25-HC leads to the downregulation of many
key genes involved in the mevalonate pathway leading to an antiviral state within the host cell. Furthermore,
dysregulation of a larger subset of genes not directly related to the mevalonate pathway occurs both in 25-HC-
treated HCV replicon harbouring cells as well as during the initial rise in viremia in infected chimpanzees.
Functional studies of 3 of these genes demonstrates that they do not directly act as antiviral gene products but
that they indirectly contribute to the antiviral state in the host cell. These genes may also represent novel
biomarkers for HCV infection, since they demonstrate an outcome-specific expression profile.
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Background
Hepatitis C virus (HCV) infection is a global health prob-
lem and a leading cause of liver disease in North America
[1,2]. Previous studies have indicated that genes associ-
ated with cellular metabolic pathways are involved in the
HCV life cycle. HCV infection causes the accumulation of
lipid droplets (LDs) in patients' hepatocytes, a process
called steatosis [3]. Both the HCV core protein and non-
structural protein NS5A are localized to LDs, replication
complexes have been demonstrated to be located in LD-
associated membranes, and that this recruitment is critical
for producing infectious viruses [4-6]. Additionally, the
expression of core protein in the liver of transgenic mice
causes the development of steatosis [7].
Altering the host cell environment by using small mole-
cules and other functional genomic approaches has been
demonstrated to modulate HCV replication through
diverse mechanisms [8-15]. Depletion of cholesterol
using β-cyclodextrin disrupts the membranous web upon
which HCV replication occurs [8]. Inhibitors of HMG-
CoA reductase, the rate-controlling enzyme of the meval-
onate pathway, like lovastatin and fluvastatin, also inhibit
HCV replication [9,10]. In addition, small molecule
inhibitors such as 25-hydroxycholesterol (25-HC) and
cerulenin, both of which act at the mevalonate pathway,
also inhibit HCV replication [11,12]. GGTI-286, an inhib-
itor of geranylgeranylation, inhibits HCV replication [13],
and FBL2 has been implicated as a geranylgeranylated
host protein required for HCV RNA replication [14]. The
PPAR receptor antagonist 2-chloro-5-nitro-N-(pyri-
dyl)benzamide also modulates HCV replication [15]. Col-
lectively, these observations implicate a direct role of
cellular lipid metabolism in the HCV life cycle and suggest
that further insight into host cell metabolic determinants
for the HCV life cycle may help to define new strategies for
the development of antiviral therapeutics.
Gene expression profiling has been used to study HCV-
associated liver pathologies, including cirrhosis [16],
fibrosis [17], and hepatocellular carcinoma (HCC) [18].
Other researchers have used microarrays to elucidate the
mechanism(s) underlying IFN resistance [19] and the
molecular basis for treatment failure of pegylated IFNα
plus ribavirin [20-23]. The progression of HCV infection
has also been studied by transcriptional profiling of liver
biopsies in acutely infected chimpanzees that developed
persistent infection, transient viral clearance, or sustained
clearance, and common as well as outcome-specific
changes in gene expression were observed [11]. Transient
and sustained viral clearance was associated with the
induction of IFNγ- induced genes, antigen processing and
presentation genes, and genes associated with the adap-
tive immune response [11]. Host genes involved in lipid
metabolism were also differentially regulated during the
early stages of infection and these genes correlated with
the outcome of infection [11]. These observations are par-
ticularly important given that HCV-derived steatosis is
correlated with more rapid disease progression and
reduced response to antiviral therapy clinically [24].
Herein we have performed gene expression profiling of
Huh-7 cells harbouring HCV replicons in the absence and
presence of the mevalonate pathway inhibitor 25-HC
(Fig. 1) and examined which differentially regulated genes
lead to an antiviral state in the replicon model. The
changes in gene expression in the replicon model were
compared with the gene expression profiles in HCV
infected chimpanzees to evaluate their role in HCV patho-
genesis.
Results
We performed transcriptome profiling using U133A
Affymetrix high-density oligonucleotide arrays on RNA
samples prepared from Huh-7 cells bearing HCV repli-
cons in the presence of 25-HC, an inhibitor of the meval-
onate pathway. The transcriptional profiling was carried
out using cRNA prepared from four treatment groups: (1)
naïve Huh-7 cells; (2) naïve Huh-7 cells treated with 25-
HC; (3) Huh-7 cells transiently transfected with pFK-
I389neo/NS3-3'/5.1 or replicon RNA from pFK-I389neo/
NS3-3'/Δ5B replicon RNAs (Fig. 2a); and (4) Huh-7 cells
transiently transfected with pFK-I389neo/NS3-3'/5.1 or
pFK-I389neo/NS3-3'/Δ5B replicon RNAs and treated with
25-HC as indicated in Fig. 2b. The experiments were per-
formed analogously to previous studies of antiviral small
molecules on HCV replication [25-27]. As previously
reported [8,11], the treatment of Huh-7 cells bearing HCV
replicons with 25-HC caused a dose-dependent decrease
in HCV replication at non-toxic concentrations as meas-
ured by firefly luciferase activity in Huh-7 cells transfected
with HCV replicon RNA from pFK-I389luc/NS3-3'/5.1 (Fig.
2a).
Comparisons were conducted between each set of dupli-
cate data to determine which genes were differentially
expressed in 25-HC-treated Huh-7 cells and in the 25-HC-
treated HCV replicon cells. The ratios of average expres-
sion for 25-HC treated Huh-7 cells/naïve Huh-7 cells were
used to compute the fold change values for the 25-HC
treated column Table 1. Similarly the 25-HC-treated HCV
replicon column in Table 1 was computed from the ratio
of average expression values from (replicon + 25-HC)/rep-
licon samples. Transcriptome profiling of Huh-7 cells
treated with 25-HC demonstrated that 69 genes were dif-
ferentially regulated. Forty-seven genes were downregu-
lated, 16 of which are clearly related to the mevalonate
pathway (Table 1). A number of membrane proteins and
oligonucleotide-binding proteins also appear to be down-
regulated (Table 1). By contrast, only 22 upregulated
genes were observed upon treatment with 25-HC (TableBMC Chemical Biology 2009, 9:2 http://www.biomedcentral.com/1472-6769/9/2
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2). None of these genes are directly involved in the meval-
onate pathway and there appears to be no functional rela-
tionship between the entries within Table 2. These
observations suggest that 25-HC acts at the transcriptional
level as a negative regulator of fatty acid and cholesterol
biosynthesis [8,11,23], and that other changes in gene
expression observed occur as secondary effects of 25-HC
treatment. It is interesting to note that Huh-7 cells treated
with both HCV replicon RNA and 25-HC did not show
identical transcriptional profiles to cells treated analo-
gously without HCV replicon RNA or to those only treated
with HCV replicon RNA or replication-defective replicon
RNA (pFK-I389neo/NS3-3'/Δ5B replicon RNA). Specifi-
cally, 5 genes were uniquely upregulated and 22 genes
were uniquely downregulated in the 25-HC-treated HCV
replicon harbouring cells (Table 3). Virtually all the genes
in Table 3 are hypothetical transcripts or genes of
unknown function. Collectively the global gene expres-
sion changes represented by Tables 1, 2, 3, represent the
transcriptional program that leads to an antiviral state
within the host cell hepatocyte, at least for the subge-
nomic HCV replicon. One or more of these genes may
serve as prognostic markers for HCV treatment. Therefore,
we performed further studies to investigate the impor-
tance of the observed gene expression changes in Tables 1,
2, 3 in other models for HCV pathogenesis.
We examined the transcriptional profiles of the genes
from this study in three previously studied chimpanzees
that were infected with HCV resulting in different out-
comes of infection [28] and for whom genome-wide tran-
scriptional analyses were performed during the course of
infection [11]. Briefly, one chimpanzee successfully
cleared the virus (sustained clearance, SC), one became
persistently infected but initially transiently cleared the
virus (transient clearance, TC), and the third chimpanzee
developed an unrestrained persistent HCV infection (per-
sistence, PS) in the absence of both an intrahepatic antivi-
ral immune response and IFN-γ induction [28]. Genome-
wide transcriptional profiling did suggest that the induc-
tion of both immunological and hepatocellular genes can
influence the course and outcome of HCV infection [11].
Both the SC and TC chimpanzees displayed an altered
lipid metabolism profile during the initial rise in viremia
following inoculation with HCV as revealed by gene
expression profiling, whereas the PS chimpanzee did not
[11].
To determine which genes from our study were most rele-
vant in the context of HCV infection in the chimpanzee
model, we compared genes identified in Tables 1, 2, 3
The mevalonate pathway Figure 1
The mevalonate pathway. Schematic diagram of the mevalonate pathway with the targets of the inhibitor 25-hydroxycho-
lesterol indicated.BMC Chemical Biology 2009, 9:2 http://www.biomedcentral.com/1472-6769/9/2
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with those of the chimpanzee data sets described previ-
ously [11]. To this end, we compared the replicon data
sets (transient transfection) with the most representative
chimpanzee data sets, those containing genes that
changed significantly during the initial rise in viremia
(described in the methods section), since both involve an
initial host response to viral RNA and both involve the
modulation of lipid metabolism genes. From the 69 dif-
HCV replicons and their use in transcriptional profiling with 25-hydroxycholesterol treatment Figure 2
HCV replicons and their use in transcriptional profiling with 25-hydroxycholesterol treatment. (a) HCV genome 
and HCV subgenomic replicon constructs used in this study. (b) Experimental design for Affymetrix GeneChip experiments 
using HCV luc/NS3-3'/5.1 replicon RNA.
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Table 1: GeneChip analysis of downregulated genes after 25-HC treatment of Huh-7 cells and Huh-7 cells bearing HCV subgenomic 
replicons.a
Descriptionb Name Accession # Fold change 25-HC-treated Fold change 25-HC-treated 
HCV replicon
1 chromosome 14 clone BAC 507E23 
map 14q24.3
B-ATF AC007182 -4.1 -6.4
2 mRNA for cysteine protease D55696.1 -3.9 ---
3 RNA binding motif protein 5 RBM5 NM_005778.1 -3.1 ---
4 tetratricopeptide repeat domain 3 TTC3 AI652848 -3.1 ---
5 insulin induced gene 1 INSIG1 BE300521 -2.8 -2.9
BG292233 -2.2 -1.9
NM_005542.1 -2.2 -2
6 SON DNA binding protein SON AA664291 -2.4 -2.4
7 3-hydroxy-3-methylglutaryl-Coenzyme A 
synthase 1 (soluble)
HMGCS1 NM_002130.1 -2.4 -2.4
8 Similar to Nedd-4-like ubiquitin-
protein ligase, clone MGC:2079
BC000108.1 -2.3 ---
9 hypothetical protein DJ328E19.C1.1 DJ328E19.C1.1 BE732345 -2.3 ---
10 Human DNA sequence from clone 
RP1-221C16 on chromosome 6
AL353759 -2.2 ---
11 low density lipoprotein receptor LDLR AI861942 -2.1 -3.3
12 3-hydroxy-3-methylglutaryl-Coenzyme A 
reductase
HMGCR AL518627 -2.1 -1.9
13 fatty acid desaturase 1 FADS1 BG165833 -2.1 -1.7
14 sterol-C5-desaturase homolog D85181.1 -2.1 ---
15 Human lanosterol 14-alpha 
demethylase
CYP51P2 U40053 -2.1 -2
16 FK506-binding protein 2 FKBP2 NM_004470.1 -2 -1.6
17 apolipoprotein AI regulatory protein ARP-1 M64497.1 -2 -3.5
18 Homo sapiens HDCMC28P protein HDCMC28P NM_016649.1 -2 ---
19 pleckstrin homology domain-
containing, family A 
(phosphoinositide binding specific) 
member 1
PLEKHA1 NM_021622.1 -2 ---
20 olfactory receptor, family 7, 
subfamily A, member 17
OR7A17 NM_030901.1 -1.9 2.4
21 sterol-C4-methyl oxidase-like SC4MOL AV704962 -1.9 -2.5
22 PRO0998 PRO0998 AF116616.1 -1.9 -2.6
23 ASMneg1-b1 immunoglobulin lambda 
chain VJ region
IGL AF043584.1 -1.9 1.7
24 bone marrow protein BM037 BM037 NM_018454.1 -1.9 ---
25 3-hydroxy-3-methylglutaryl-Coenzyme A 
synthase 1
HMGCS1 BG035985 -1.9 -2.6
26 farnesyl diphosphate synthase FDPS NM_002004.1 -1.8 -1.8
27 mevalonate (diphospho) decarboxylase MVD AI189359 -1.8 -3.1
28 kinesin family member 3C KIF3C NM_002254.1 -1.8 ---
29 peptidyl-prolyl isomerase G 
(cyclophilin G)
PPIG AW340788 -1.8 ---
30 acetyl-Coenzyme A acetyltransferase 2 BC000408.1 -1.8 -1.6
31 farnesyl-diphosphate farnesyltransferase 
1
BC003573.1 -1.8 -2
32 Homo sapiens Kruppel-like factor LOC51713 NM_016270.1 -1.8 -2.4
33 prospero-related homeobox 1 PROX1 NM_002763.1 -1.7 ---
34 cDNA FLJ13484 fis, clone 
PLACE1003888
AK023546.1 -1.7 ---
35 M10098 Human 18S rRNA sequence -1.7 ---
36 chromodomain helicase DNA 
binding protein 4
CHD4 AI761771 -1.6 -2.1
37 topoisomerase (DNA) II alpha 
170kDa
TOP2A AU159942 -1.6 ---
38 7-dehydrocholesterol reductase DHCR7 AW150953 -1.6 -2.2
39 vesicle docking protein p115 VDP BE875592 -1.6 -1.5BMC Chemical Biology 2009, 9:2 http://www.biomedcentral.com/1472-6769/9/2
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40 v-crk avian sarcoma virus CT10 
oncogene homolog
CRK NM_016823.1 -1.6 1.7
41 Nijmegen breakage syndrome 1 
(nibrin)
NBS1 AI796269 -1.6 ---
42 farnesyl-diphosphate farnesyltransferase 
1
FDFT1 AA872727 -1.6 -2.2
43 cDNA FLJ11371 fis, clone 
HEMBA1000356
AK021433.1 -1.6 ---
44 PAC clone RP5-979P20 from 7 NPM1P12 AC004941 -1.6 -1.5
45 erythrocyte membrane protein band 
4.1-like 2
EPB41L2 BF511685 -1.5 1.9
46 activated leukocyte cell adhesion 
molecule
ALCAM BF242905 -1.5 -1.7
47 protein kinase related to S. 
cerevisiae STE20
PAK4 NM_005884.2 -1.5 ---
48 cDNA: FLJ21342 fis, clone 
COL02673.
AK024995.1 -1.5 ---
a Fold change was calculated from the average of two independent hybridizations on U133A Affymetrix GeneChip arrays compared with an average 
expression value from analogous hybridizations from control cells that were not treated with 25-HC. Fold change for 25-HC-treated column was 
determined from the ratio of expression in 25-HC treated Huh-7 cells/naïve Huh-7 cells and for the 25-HC-treated HCV replicon column from the 
ratio of expression values from (replicon + 25-HC)/replicon. b Italicized entries are known to be involved in the mevalonate pathway. Dashes (---) 
indicate genes whose fold-change in gene expression did not exceed 1.5-fold and hence were omitted from the analysis.
Table 1: GeneChip analysis of downregulated genes after 25-HC treatment of Huh-7 cells and Huh-7 cells bearing HCV subgenomic 
replicons.a (Continued)
Table 2: GeneChip analysis of upregulated genes after 25-HC treatment of Huh-7 cells and Huh-7 cells bearing HCV subgenomic 
replicons.a
Description Name Accession # Fold change 25-HC-treated Fold change 25-HC-treated 
HCV replicon
1 cytochrome P450-IIB hIIB3 M29873.1 1.5 1.5
2 BTG family, member 2 BTG2 NM_006763.1 1.6 ---
3 epithelial membrane protein 3 EMP3 NM_001425.1 1.6 ---
4 gro-beta GROB M57731.1 1.6 ---
5 S100 calcium-binding protein A6 
(calcyclin)
S100A6 NM_014624.2 1.6 -1.6
6 KIAA0063 gene product KIAA0063 NM_014876.1 1.7 ---
7 acetyl-Coenzyme A carboxylase alpha ACACA BE855983 1.7 -2.9
8 HUMBT Chromosome 16p13.3 Exon 
Homo sapiens genomic clone h-80
L48784 1.7 -2.4
9 centrin, EF-hand protein, 2, clone 
MGC:12421
BC005334.1 1.8 2
10 intercellular adhesion molecule 1 
(CD54), human rhinovirus receptor
ICAM1 AI608725 1.9 1.6
11 diubiquitin UBD NM_006398.1 1.9 1.5
12 cDNA DKFZp564P1263 
(from clone DKFZp564P1263)
AL136653.1 1.9 3.4
13 H. sapiens hGDS mRNA for smg GDS. X63465.1 1.9 2.1
14 actin related protein 23 complex, 
subunit 4
ARPC4 NM_005718.1 1.9 ---
15 natural killer cell transcript 4 NK4 NM_004221.1 2 -1.6
16 ATX1 (antioxidant protein 1, yeast) 
homolog 1
ATOX1 NM_004045.1 2.2 ---
17 Human DNA with a hepatitis B virus 
surface antigen (HBsAg) gene
M20919 2.7 1.6
a Fold change was calculated from the average of two independent hybridizations on U133A Affymetrix GeneChip arrays compared with an average 
expression value from analogous hybridizations from control cells that were not treated with 25-HC. Fold change for 25-HC-treated column was 
determined from the ratio of expression 25-HC treated Huh-7 cells/naïve Huh-7 cells and for the 25-HC-treated HCV replicon column from the 
ratio of expression values from (replicon + 25-HC)/replicon. Dashes (---) indicate genes whose fold-change in gene expression did not exceed 1.5-
fold and hence were omitted from the analysis.BMC Chemical Biology 2009, 9:2 http://www.biomedcentral.com/1472-6769/9/2
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ferentially regulated genes identified here and the 257
genes derived from transcriptome profiling of infected
chimpanzees during the initial rise in viremia [11], we
identified 54 overlapping genes. These genes were further
analyzed based on outcome-specific gene expression pro-
files, fold-induction in chimpanzees during the initial rise
in viremia, function as determined by bioinformatically
and using the SymAtlas at http://symatlas.gnf.org/SymAt
las, and using the Ingenuity interaction software. The four
genes selected for further study were prospero-related
homeobox 1 (PROX1), insulin induced gene 1 (INSIG1),
natural killer cell transcript 4 (NK4), and diubiquitin
(UBD), Table 4.
The PROX1 gene is a transcription factor expressed in the
adult human liver that is involved in hepatocyte specifica-
tion, proliferation, differentiation, and migration [29]. It
is also involved in control of bile acid synthesis and cho-
lesterol homeostasis in vivo [30]. Since HCV replication
has been demonstrated to be linked with cellular lipid
metabolism, and the PROX1 gene was found to have
interesting expression patterns in previous gene expres-
sion studies carried out in chimpanzee [11,30], the
PROX1 gene was chosen for further validation in the HCV
replicon cells. In the replicon data set, PROX1 was down-
regulated in HCV replicon cells compared with naïve
Huh-7 cells (Table 4). The PROX1 gene is downregulated
in replicon-harbouring cells compared to naïve Huh-7
cells and represents a class of genes that may be negatively
regulated during HCV replication. Interestingly, PROX1 is
upregulated in TC and SC during the initial rise in
viremia, but negatively regulated in PS (Table 4).
The INSIG-1 is highly expressed in the adult liver and
plays a role in sterol homeostasis. INSIG-1 was downreg-
ulated in 25-HC-treated HCV replicon cells compared
Table 3: GeneChip analysis of gene expression changes after 25-HC treatment in HCV replicons.a
Description Name Accession # Fold change 25-HC-treated Fold change 25-HC-treated 
HCV replicon
1 KIAA0552 gene product KIAA0552 NM_014731.1 --- -3.5
2 solute carrier family 29 (nucleoside 
transporters), member 1
SLC29A1 NM_004955.1 --- -3
3 clone 25061 AF131777.1 --- -2.8
4 protein predicted by clone 23627 
(HSU79266)
HSU79266 NM_013299.1 --- -2.5
5 hypothetical protein FLJ22390 FLJ22390 NM_022746.1 --- -2.3
6 Cip1-interacting zinc finger protein CIZ1 NM_012127.1 --- -2.1
7 protein phosphatase 4, catalytic 
subunit, clone MGC:1882
BC001416.1 --- -2.1
8 CGI-28 protein LOC51073 NM_015956.1 --- -2.1
9 mitochondrial Rho 2 MIRO-2 AI186666 --- -2.1
10 ribosomal protein L13 RPL13 AA789278 --- -2
11 chromosome 19, fosmid 39554 fos39554_1 AC004410 --- -2
12 hypothetical protein MGC3180 MGC3180 NM_024041.1 --- -1.9
13 EST, Weakly similar to FLJ14827 [H. 
sapiens]
FLJ14827 BE966197 --- -1.9
14 hypothetical protein 
DKFZp547L134
DKFZp547L134 NM_016553.1 --- -1.8
15 NADH dehydrogenase 1 alpha 
subcomplex, 7
NDUFA7 NM_005001.1 --- -1.6
16 hypothetical protein MGC8407 MGC8407 NM_024046.1 --- 1.5
17 Homo sapiens full length insert 
cDNA YH77E09
YH77E09 AA928506 --- 1.6
18 hypothetical protein FLJ12668 FLJ12668 NM_024997.1 --- 2
19 cDNA FLJ10958 fis, clone 
PLACE1000444.
AU155621 --- 2.9
20 hypothetical protein FLJ20556 FLJ20556 NM_017878.1 --- 3.6
21 Similar to cadherin 6, type 2, K-
cadherin (fetal kidney), clone 
MGC:1470
BC000019.1 --- 4.1
a Fold change were calculated from the average of two independent hybridizations on U133A Affymetrix GeneChip arrays compared with an 
average expression value from analogous hybridizations from control cells that were not treated with 25-HC. Fold change for 25-HC-treated 
column was determined from the ratio of expression 25-HC treated Huh-7 cells/naïve Huh-7 cells and for the 25-HC-treated HCV replicon column 
from the ratio of expression values from (replicon + 25-HC)/replicon. Dashes (---) indicate genes whose fold-change in gene expression did not 
exceed 1.5-fold and hence were omitted from the analysis.BMC Chemical Biology 2009, 9:2 http://www.biomedcentral.com/1472-6769/9/2
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with HCV replicon-harbouring cells (Table 4). INSIG-1
represents a class of genes that are negatively regulated
during HCV replication under metabolic conditions that
are induced by the inhibitor of the mevalonate pathway,
25-HC. This transcript is also upregulated in an outcome-
specific manner in the chimpanzee who experienced a
clearance episode (SC and TC) but not in that which
resulted in a persistent (PS) infection (Table 4).
The NK4 gene was chosen for further validation because
its expression seems to be correlated with a clearance state
in the chimpanzee and it was found to be upregulated in
the 25-HC-treated HCV replicon cells compared with
naïve Huh-7 cells treated with 25-HC (Table 4). Unlike
PROX1 and INSIG1, NK4 represents a class of genes that
are induced upon HCV replication and appears to be
modulated by treatment with 25-HC.
Finally, the UBD gene was chosen for further validation
because its expression was increased dramatically in the
chimpanzees associated with sustained and transient
clearance, 43-fold and 7-fold, respectively, and it was
upregulated in 25-HC-treated HCV replicon cells com-
pared with naïve Huh-7 cells treated with 25-HC (Table
4). UBD represents a class of genes that are induced dur-
ing HCV replication when an antiviral state exists within
the host cell, as demonstrated by the increase in expres-
sion in HCV replicon harbouring cells treated with 25-
HC. This gene may serve as a prognostic marker for HCV
infection.
Next we examined the overall gene expression patterns for
these four genes (Table 4) in the TC, SC, and PS chimpan-
zees. The expression levels of the four genes in infected
chimpanzees were plotted as a function of time alongside
the HCV RNA levels measured in the chimpanzees [11]
(Fig. 3). The comparative analysis between the chimpan-
zee and replicon data sets was done based on the first
three chimpanzee time points, which corresponded to the
initial rise in viremia [11]. However, the expression of the
four genes of interest was determined and plotted for the
entire measured time course of infection for the chimpan-
zees in Fig. 4. In general, the gene expression levels of the
four genes paralleled the HCV levels in the chimpanzees
that displayed sustained clearance (SC) and transient
clearance (TC) of HCV. The overall gene expression levels
were lowest in the persistently infected (PS) chimpanzee
compared to the SC and TC chimpanzees. Also, the overall
gene expression levels were higher for all four genes in the
TC chimpanzee, which also had the highest viral titres
(Fig. 4).
Expression of PROX1 in the HCV-infected chimpanzees
early post-infection decreased slightly within the first six
days for the SC chimpanzee, increased within the first
eight days in the TC chimpanzee, and decreased within
the first eight days in the PS chimpanzee (Fig. 4).
Throughout the remaining course of infection, PROX1
levels roughly correlated with HCV levels in the SC and TC
chimpanzees, while in the PS chimpanzee the PROX1 lev-
els remained lower than the HCV levels. The expression
level of INSIG-1 early post-infection increased in the SC
Table 4: Comparative gene expression analysis of 25-HC-treated and HCV replicon-harboring Huh-7 cells with the changes in gene 
expression during HCV infection in chimpanzees with different outcomes of infection.a
Fold Change in Gene Expression over Naïve Huh-7 
cells
Fold Change in Gene Expression during the Initial 
Rise in Viremiac
Name Accessio
n #
Naïve 
Huh-7 + 
25-HC
Huh-7 + 
luc/NS3-3'/
Δ5B
Huh-7 + 
luc/NS3-3'/
5.1
Huh-7 + luc/
NS3-3'/5.1 + 
25-HC
Naïve 
Chimpanz
ee
Sustained 
Clearance 
(SC)
Transient 
Clearance 
(TC)
Persistenc
e (PS)
PROX1 NM_0027
63.1
-1.7 -2.0 -2.0 -1.9 --- 3.5 1.6 -2.3
INSIG1b BG292233 -2.2 --- --- -1.8 --- 1.6 2.9 ---
BE300521 -2.8 --- --- -2.8 N/A N/A N/A N/A
NM_0055
42.1
-2.2 --- --- -1.8 N/A N/A N/A N/A
NK4 NM_0042
21.1
2.0 4.6 2.9 1.9 --- 2.4 2.7 ---
UBD NM_0063
98.1
1.9 1.6 1.7 2.5 --- 7.2 42.7 ---
a Comparisons were made with data collected from reference [11] for transcriptional profiles of 4 chimpanzees with different outcomes of viremia. 
See reference [11] for the details of the experiments for transcriptional profiling. The transcriptional profiling data from reference [11] was simply 
mined for the relevant data presented in this table; b Multiple INSIG1 Accessions correspond to the three INSIG1 probes; c Initial Rise in Viremia 
indicates gene expression levels at timepoint 3 after infection over timepoint 1 just prior to infection for each chimpanzee. Dashes (---) indicate 
genes whose fold-change in gene expression did not exceed 1.5-fold and hence were omitted from the analysis. N/A indicates transcripts that were 
not assessed in the chimpanzee gene expression profiles.BMC Chemical Biology 2009, 9:2 http://www.biomedcentral.com/1472-6769/9/2
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and TC chimpanzees while it varied only slightly within
the first eighteen days post-infection in the PS chimpan-
zee (Fig. 4). Thereafter, the INSIG-1 levels closely paral-
leled the HCV RNA levels in the SC and TC chimpanzees
and rose to meet the HCV level in the PS chimpanzee. The
NK4 levels during the initial rise in viremia in the chim-
panzees paralleled the rising HCV levels in the SC and TC
chimpanzees (Fig. 4). In contrast, in the PS chimpanzee
the NK4 levels decreased within the first eight days of
infection and then increased along with the rising HCV
RNA level. Finally, the UBD pattern of expression basi-
cally paralleled the levels of HCV RNA in the SC and TC
chimpanzees with some variation in the absolute levels of
expression relative to that of the HCV RNA (Fig. 4). In the
PS chimpanzee, the UBD expression level remained close
to baseline levels in the first eighteen days post-infection,
and then the UBD expression steadily increased during
the remaining time course of HCV infection.
To ascertain the importance of the four genes for HCV rep-
lication, siRNA knockdown and overexpression studies
were carried out in Huh-7 cells harbouring HCV replicon
RNA. RT-PCR and northern blot analyses were used to
confirm siRNA and overexpression vector function in each
case (data not shown). Huh-7 cells stably expressing neo/
luc/NS3-3'/5.1 HCV replicons [8,25-27] were treated with
siRNAs against the four genes in the absence or presence
of 25-HC (Fig. 5A). As controls, the HCV replicon cells
were also treated with GL2 and GL3 siRNAs, a positive
control that targets the luciferase gene expressed from the
HCV replicon RNA and a negative control, respectively, in
addition to IFNγ treatment [15]. Interestingly, although
the PROX1 siRNA did not affect HCV replication on its
own, it enhanced the inhibitory effect of treatment with 5
μM 25-HC when compared to mock-transfected replicon
cells treated with 5 μM 25-HC (p < 0.01) as indicated (Fig.
5A). Overexpression of PROX1 in replicon cells did not
affect HCV replication (Fig. 5C). Knockdown of INSIG-1
with homologous siRNAs did not affect HCV replication
in replicon cells either in the absence or presence of 25-
HC (Fig. 5A). Similarly, overexpression of INSIG-1 in rep-
licon cells did not affect HCV replication (Fig. 5C).
Although the transcriptional profiling showed that NK4
was upregulated in replicon cells treated with 25-HC,
siRNA knockdown of NK4 did not affect HCV replication
(Fig. 5A). However, overexpression of NK4 affected HCV
replication in the presence of 25-HC treatment, causing a
significant decrease in HCV replication compared to rep-
licon cells that were transfected with the backbone β-gal
control vector and treated with 25-HC (p < 0.05; Fig. 5C).
From the profiling data, UBD was upregulated in 25-HC-
treated replicon cells compared with naïve Huh-7 cells
treated with 25-HC. However, neither knockdown of
UBD using siRNA duplexes (Fig. 5A) nor overexpression
of UBD (Fig. 5C) had an affect on HCV replication.
To determine if siRNA treatment or overexpression had
any affect on the expression of the HCV nonstructural pro-
teins NS3 and NS5A, Huh-7 cells stably expressing neo/
NS3-3'/5.1 replicons were transiently transfected with
Inhibition of HCV RNA replication by 25-hydroxycholesterol in a dose-dependent manner Figure 3
Inhibition of HCV RNA replication by 25-hydroxycholesterol in a dose-dependent manner. Activity data from 
Huh-7 cells transiently transfected with luc/NS3-3'/5.1 replicon RNA and treated with 25-HC or 100 U/ml IFNγ for 24 h. Bars 
represent the mean ± standard deviation of triplicate samples. An asterisk above a bar indicates a significant decrease in repli-
cation compared to untreated cells (p < 0.01).
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siRNA or overexpression constructs and western blot anal-
yses were conducted. As expected, siRNA knockdown of
PROX1 gene expression resulted in complete loss of
PROX1 protein expression (Fig. 5B). However, knock-
down of PROX1 expression did not have any affect on
NS3 or NS5A protein levels (Fig. 5B). Corresponding to
their negative effect on HCV replication, IFNγ and 25-HC
treatment of replicon cells caused a decrease in the levels
of NS3 and NS5A, with the effect being more pronounced
for NS5A as we had previously reported [25]. Interest-
ingly, overexpression of INSIG-1 caused an increase in the
levels of both HCV non-structural proteins (Fig. 5C).
Overexpression of NK4 and UBD had no effect on the lev-
els of HCV non-structural proteins (Fig. 5D).
Discussion
Several examples now exist whereby HCV replication can
be modulated or even cured by the targeting of host cell
pathways rather than through the direct targeting of the
virus [8,11,13-15,25-27]. Any perturbation of a host cell
pathway that is harnessed or diverted by HCV during its
life cycle has the potential to be an antiviral target, partic-
ularly if it is not an essential pathway to cell function.
Small molecule probes have been used to block HCV rep-
lication by preventing the replication complexes from
Gene expression patterns for PROX1, INSIG-1, NK4, and UBD in HCV- infected chimpanzees Figure 4
Gene expression patterns for PROX1, INSIG-1, NK4, and UBD in HCV- infected chimpanzees. Expression pat-
terns of genes that are differentially regulated in HCV replicon cells during a time course of HCV infection for three infected 
chimpanzees displaying different outcomes of infection (SC, TC, and PS) [11]. Green lines represent log HCV RNA patterns, 
with values below the threshold for detection represented by zero.
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The effect of 25-hydroxycholesterol and siRNA knockdown or gene overexpression on HCV RNA replication and translation Figure 5
The effect of 25-hydroxycholesterol and siRNA knockdown or gene overexpression on HCV RNA replication 
and translation. Huh-7 cells stably expressing neo/luc/NS3-3'/5.1 or neo/NS3-3'/5.1 subgenomic replicons were transiently 
transfected with siRNA duplexes homologous to the genes of interest (A and B) or with expression plasmids for the genes of 
interest (C and D) in the absence or presence of 5 μM 25-hydroxycholesterol (25-HC) for 48 hours. After siRNA knockdown 
or overexpression of target genes, cell lysates were analyzed for luciferase activity (A and C) and western blot analysis of HCV 
non-structural proteins NS3 and NS5A as well as PROX1 (B and D). GL2 and GL3 siRNAs were used as controls for siRNA 
knockdown as described in the Methods. Mock refers to cells that were incubated with the transfection reagent but without 
siRNA or plasmid. As a positive control, cells were separately treated with 100 U/ml IFNγ. Values in (A) and (C) are the mean 
normalized relative light units (RLU) per mg/ml of protein ± standard deviation from triplicate samples. For the siRNA knock-
down (A), an asterisk above a bar indicates a significant decrease in HCV replication compared to mock-transfected cells (GL2, 
PROX-1; p < 0.01) or untreated cells (IFNγ; p < 0.01) in the presence of 5 μM 25-HC. For the overexpression studies (C), an 
asterisk above a bar indicates a significant decrease in HCV replication compared to cells transfected with the backbone β-gal 
vector (NK4; p < 0.05) or the untreated cells (IFNγ; p < 0.01) when compared to the appropriate treatment condition (no 
treatment or 5 μM 25-HC treatment as indicated).
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forming [8,11,13,14], by the selective inhibition of host
cell kinases [26], by targeting nuclear hormone receptors
[15], and by blocking protein folding pathways [27]. 25-
HC has been established to yield an antiviral state within
Huh-7 cells by modulating the mevalonate pathway
[8,11,13,14]. To better understand the nature of the
changes induced to the host cell, we performed global
transcriptional profiling of Huh-7 cells and Huh-7 cells
bearing HCV replicons. We identified unique sets of genes
that are both up- and downregulated by 25-HC and estab-
lished the transcriptional changes that lead to the inhibi-
tion of HCV replication in Huh-7 cells. By comparing
these transcriptional profiles (Tables 1, 2, 3) with the gene
expression profiles of HCV-infected chimpanzees we
identified a number of transcripts that may be important
for HCV pathogenesis. These genes may also be prognos-
tic markers for disease progression and outcome that are
indicative of the antiviral state of the host cell. From the
54 overlapping genes, we identified four genes for further
study (Table 4), in an effort to establish a marker for HCV
outcome that was linked to the transcriptional state of the
host cell.
PROX1 is a highly conserved transcription factor that is
expressed in hepatocytes and is involved in proliferation
and migration [29]. It is also involved in the control of
bile acid synthesis and cholesterol homeostasis in vivo
[30]. The down-regulation of PROX1 in replicon cells
compared to naïve Huh-7 cells suggests that PROX1 may
negatively influence HCV replication but that this effect
may only occur under certain metabolic conditions. The
down-regulation of PROX1 was observed in the HCV rep-
licon cells treated with 25-HC. Contrary to this, PROX1
expression was observed to rise early post-infection in the
SC and TC chimpanzees (Fig. 4). The decreased expression
of PROX1 in the chimpanzee with a persistent HCV infec-
tion suggests that PROX1 may be a predictor of the out-
come of viremia. Dysregulation of PROX1 was also
independently observed in another HCV-infected chim-
panzee [31]. However, the fold changes observed for
PROX1 may in fact be too small to act as a reliable prog-
nostic marker for clinical applications.
INSIG-1 is highly expressed in the liver and plays an
essential role in sterol homeostasis. INSIG-1 inhibits the
sterol-dependent retention of the SCAP/SREBP complex
in the ER and accelerates the sterol-stimulated degrada-
tion of HMG-CoA reductase, thus regulating the expres-
sion of cholesterol, fatty acids, and triglycerides [32,33].
Early post-infection, the expression level of INSIG-1
increased in the SC and TC chimpanzees and slightly
decreased in the PS chimpanzee (Fig. 4), suggesting that
this gene acts as an early metabolic predictor of outcome.
Like 25-HC, INSIG-1 is an HMG-CoA reductase inhibitor
and, therefore, it would be expected to decrease HCV rep-
lication. Since we did not observe any change in HCV rep-
lication with the INSIG-1 siRNA treatment, we can only
conclude that the kinetics of siRNA knockdown of INSIG-
1 were too slow to give rise to significant changes in HMG-
CoA reductase during the course of the experiment, given
that the INSIG-1 siRNA sequences had been previously
validated [23]. Interestingly, overexpression of INSIG-1
caused an increase in the levels of HCV proteins NS3 and
NS5A, which may be the result of a homeostatic response
(Fig. 5D). The fold change values observed for INSIG1
may also limit its ability to serve as a prognostic marker.
NK4 was discovered by differential screening of a cDNA
library derived from human NK cells that were activated
by interleukin-2 [34]. Our observation that NK4 levels
were increased early in viremia in the SC and TC chimpan-
zees (Fig. 4) is consistent with a previous report of
increased NK4 expression in an HCV-infected chimpan-
zee [31]. NK4 was also upregulated in replicon cells
treated with 25-HC (Table 2), suggesting that it may con-
tribute to the suppression of replication caused by 25-HC.
Taken together, the data suggests that NK4 may be a co-
factor in inhibiting HCV replication, but it is not sufficient
on its own to clear the virus in a persistent infection.
Diubiquitin (UBD, FAT10) is an alternative and ubiquitin-
independent targeting mechanism for degradation by the
proteasome [35]. UBD expression is inducible with IFNγ
and TNF-α [36], both of which are well known antiviral
cytokines. Additionally, previous gene expression profiling
in HCV-infected chimpanzees identified differential regula-
tion of proteasome genes [11,31,37]. From the profiling
data derived from the HCV replicon cells, UBD was upreg-
ulated in 25-HC-treated replicon cells compared with naïve
Huh-7 cells treated with 25-HC. This suggests that upregu-
lation of proteasome degradation of HCV proteins may be
an ancillary effect of 25-HC treatment. Neither knockdown
of UBD using siRNA complexes nor overexpression of UBD
had an affect on HCV replication in Huh-7 cells (Fig. 5),
indicating that UBD is not a target for the development of
potential therapeutic strategies for HCV infection. Rather,
the very large fold change values observed, particularly in
the large animal model for infection, suggests that it is a
good candidate prognostic marker for an antiviral state
within the host cell.
Conclusion
Herein we have established the transcriptional changes
that give rise to an antiviral state that inhibits HCV repli-
cation within Huh-7 cells after treatment with 25-HC. We
identified four genes that can act as markers for HCV
pathogenesis. The functional validation studies showed
that none of these genes are likely to be useful as antiviral
drug targets, they were identified as being linked to an
antiviral state in the HCV replicon cells and in chimpan-
zee infections. Not surprisingly, INSIG1 and PROX1 tran-
scriptional levels are related to regulation of theBMC Chemical Biology 2009, 9:2 http://www.biomedcentral.com/1472-6769/9/2
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mevalonate pathway. The fact that these genes are differ-
entially regulated in different models of HCV pathogene-
sis further supports their relevance. In the case of PROX1
and NK4, effects on HCV replication were observed in cell
culture but only in certain metabolic states induced by the
presence of 25-HC. The overall expression levels of all
four genes were the lowest in the persistently infected
chimpanzee which suggests that these genes may be pre-
dictors of the outcome of infection and might ultimately
indicate a particular course of treatment on an individual
patient basis. UBD appears to be the most promising since
it was observed to have the largest changes in transcrip-
tional levels in the chimpanzee model.
Methods
Cell culture
Cell monolayers of the human hepatoma cell line Huh-7
were grown in Dulbecco's modified minimal essential
medium (DMEM) (Invitrogen, Burlington, Ontario) sup-
plemented 10% with fetal bovine serum (FBS) (Cansera,
Rexdale, Ontario) and with 100 nM non-essential amino
acids (NEAA), 50 U/ml penicillin, and 50 μg/ml strepto-
mycin. The medium was further supplemented with G418
to a concentration of 250 μg/ml for Huh-7 cells that stably
expressed HCV replicons.
HCV subgenomic replicons
The pFK-I389neo/NS3-3'/5.1, pFK-I389luc/NS3-3'/5.1, and
pFK-I389neo/NS3-3'/Δ5B plasmids that contain HCV sub-
genomic replicons [8,22] were obtained from Ralf Barten-
schlager (Institute of Hygiene, University of Heidelberg,
Heidelberg, Germany). The replicons harbor either the
selectable marker neoR (pFK-I389neo/NS3-3'/5.1 and pFK-
I389neo/NS3-3'/Δ5B) or the firefly luciferase gene (pFK-
I389luc/NS3-3'/5.1) at the 5' end, but otherwise are identi-
cal and express HCV nonstructural proteins (NS3 to
NS5B) from the encephalomyocarditis virus (EMCV)
internal ribosomal entry site (IRES). The pFK-I389neo/
NS3-3'/Δ5B plasmid carries an in-frame 10-amino acid
deletion (Δ) encompassing the active site of the NS5B
RNA polymerase that generates a replication defective rep-
licon [22] (Fig. 2A). Additionally, a tricistronic HCV sub-
genomic replicon construct, pFK-I389neo/luc/NS3-3'/5.1,
was also used in this study. This construct harbors both
neoR  and firefly luciferase, with neoR  being translated
from the HCV IRES, and the firefly luciferase and HCV
nonstructural ORF translated from separate EMCV IRES
motifs [8] (Fig. 2A). All plasmid constructs were con-
firmed by sequencing.
In vitro transcription and transient transfection of 
replicon RNAs for total RNA extraction
In vitro transcripts of HCV replicon RNAs were generated
using the MEGAscript™ kit (Ambion, Austin, Texas)
according to the manufacturer's protocol and as described
previously [8]. Huh-7 cells were seeded at 5 × 105 cells in
60 mm dishes to obtain cells at 70 to 80% confluency the
next day. The second day, the cells were washed twice with
1× PBS, pH 7.4 (Gibco/Invitrogen, Burlington, Ontario),
and once with serum- and antibiotic-free DMEM-NEAA.
Transfection complexes were prepared by mixing 5 μg of
in vitro transcribed replicon RNA (either luc/NS3-3'/5.1 or
neo/NS3-3'/Δ5B) and 30 μl of DMRIE-C (Gibco/Invitro-
gen) in 1.5 ml of serum- and antibiotic-free DMEM-NEAA
for each dish. The lipid-RNA complexes were immediately
added to the washed cells and incubated for 4 h before
commencing treatments. Mock-transfected cells received
only the DMRIE-C reagent without any RNA.
25-HC and IFN  treatments
Four hours post-transfection, the medium containing the
lipid:RNA complexes was removed and replaced by
DMEM-NEAA supplemented 10% with FBS ± 2 μM 25-
HC. The cells were treated for 24 h before the lysates were
prepared. As a positive control, some cells were treated
with IFNγ (PBL Biomedical Laboratories, Piscataway, NJ)
at a concentration of 100 U/ml. Mock-transfected cells
were exposed to the treatment solvent, typically ethanol.
Total RNA preparation for microarray experiments
Total RNA was prepared using the RNeasy® Mini kit (QIA-
GEN, Mississauga, Ontario) and following the manufac-
turer's protocol. The RNA was quantified using the
NanoDrop® ND-1000 Spectrophotometer, and the quality
of the RNA was verified using the RNA 6000 PicoLabChip
kit (Agilent Technologies, Mississauga, Ontario).
Gene expression analyses
Cellular cRNA samples were prepared and hybridized to
high-density oligonucleotide arrays (Affymetrix U133A
Human GeneChips) in the same manner as was done for
the chimpanzeeanzee samples in our previous study [11].
Each sample was hybridized in duplicate. The neo/NS3-3'/
Δ5B profiles were used as a negative control for HCV repli-
cation. Primary analyses were performed as described pre-
viously [11]. Briefly, the 116 genes identified as being
differentially regulated in the replicon data set represent the
logarithm-transformed genes that were deemed "present"
and whose average difference exceeded 150 in at least one
of the samples described above. Comparative analysis
between the chimpanzee and replicon data sets was done
based on the first three chimpanzee time points, which cor-
responded to the initial rise in viremia [11]. The post-infec-
tion time points corresponded to weeks -1, 6, and 9 for the
SC chimpanzee, weeks -1, 5, and 9 for the TC chimpanzee,
and weeks 0, 8, and 14 for the PS chimpanzee. The micro-
array data was submitted to GEO http://ncbi.nih.gov/geo
with accession numbers GSM348423-GSM348433.
Plasmids
Either the pCMV-SPORT6 vector (Invitrogen, Burlington,
ON) or the pCMV-β vector (Clontech, Mountain View,BMC Chemical Biology 2009, 9:2 http://www.biomedcentral.com/1472-6769/9/2
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CA) was used for gene overexpression. The pCMV-β vector
had the β-galactosidase gene removed using NotI  sites
before subcloning the gene of interest. Dr. Anthony Orth
[Genomics Institute of the Novartis Research Foundation
(GNF), San Diego, CA] kindly provided the diubiquitin
(UBD) construct in pCMV-SPORT6 by and the Natural
Killer transcript 4 (NK4) construct in the pOTB7 Dro-
sophila vector. The NK4 gene was subcloned into pCMV-
β via a PCR-based strategy using XhoI and NotI restriction
enzymes. A construct containing the prospero-related
homeobox 1 (PROX1) gene was made by PCR-amplifying
the gene from cDNA prepared from naïve Huh-7 cells, fol-
lowed by a second round of PCR to add NotI sites to both
ends, and subsequent subcloning into pCMV-β. The insu-
lin-induced gene 1 (INSIG-1) construct in pCMV-SPORT6
was obtained from the ATCC (Manassas, VA).
Treatment of HCV replicons with siRNAs or 
overexpression constructs
All siRNA duplexes were purchased from Dharmacon
(Lafayette, CO). siRNAs homologous to GL2 luciferase
and GL3 luciferase were used as positive and negative con-
trols, respectively, as described previously [8]. Two cus-
tom siRNA duplexes homologous to the INSIG-1 mRNA
sequence (UCA GUA UAC AUC CCC AGA U) and the
INSIG-1 genomic sequence (UCA GUA UAC GUC CCC
AGA U) were also purchased [23]. siRNA duplexes homol-
ogous to PROX1, NK4, and UBD were obtained from the
siGENOME collection. For treatment of HCV replicons
with siRNAs or overexpression constructs, Huh-7 cells sta-
bly expressing neo/luc/NS3-3'/5.1 HCV replicons were
seeded at 5 × 104 cells per well in 24-well plates the day
before transfection. The next day, 700 ng of plasmid DNA
or 725 ng of siRNA was incubated for 20 min at room
temperature with 1.4 μl (for DNA) or 1.45 μl (for siRNA)
of Lipofectamine™ 2000 in 500 μl of serum- and antibi-
otic-free DMEM-NEAA. The DNA-lipid or siRNA:lipid
complexes were then transferred onto the cells. Four
hours later, the complexes were removed and 500 μl of
DMEM-NEAA supplemented 10% with FBS was added to
the cells and the different assays were done 48 h post-
transfection. When a transient transfection was done to
prepare whole cell lysates for western blot analyses, Huh-
7 cells stably expressing neo/NS3-3'/5.1 replicons were
seeded in 60 mm dishes with all quantities scaled up 10-
fold.
Luciferase reporter assay, total protein quantification, and 
western blot analysis
Replication of HCV replicon RNA was determined using a
luciferase reporter assay as described previously [8]. Luci-
ferase assay values were normalized by the total protein
content of each sample and are shown as the mean ±
standard deviation. The total protein content of whole cell
lysates was quantified using the Bio-Rad DC Protein Assay
(Bio-Rad, Mississauga, Ontario) as described previously
[8]. Western blot analysis of whole cell protein lysates was
carried out as reported previously [15] using the antibod-
ies described below.
Antibodies
The anti-PROX1 polyclonal antibody (Upstate, Char-
lottesville, VA) was used at a dilution of 1:4000 (v/v). Two
monoclonal antibodies against the HCV nonstructural
proteins NS3 and NS5A (Virostat, Portland, ME) were
used at a 1:500 dilution (v/v). As a loading control, an
anti-β-tubulin monoclonal antibody (BD Transduction
Laboratories, Mississauga, Ontario) was used at a 1:1000
dilution (v/v). A goat anti-mouse HRP-conjugated sec-
ondary antibody (Jackson ImmunoResearch, West Grove,
PA) was used at a dilution of 1:1000 (v/v) and a donkey
anti-rabbit IgG (Jackson ImmunoResearch) was used at a
dilution of 1:3000 (v/v).
Statistics
Statistical analyses were carried out using GraphPad Prism
software (version 4.01, GraphPad Software, San Diego,
CA). Data was analyzed using one-way ANOVA. When
overall differences were detected, Dunnett's post-test was
performed to compare treatment groups to the appropri-
ate control group. A p value of 0.05 or less was considered
to be significant.
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